Abstract | AIM: PATIENTS AND METHODS: All 8 patients suffered from progressive loss of vision caused by exudation into the macular area. PDT with a verteporfin dose of 6 mg/m(2) body surface area and a light dose of 100 J/cm(2) at 692 nm was carried out. Two to four treatments were applied at 6 week intervals using a single laser spot. Standardized evaluation was used before and at 6-week intervals after each treatment and at 3, 6 and 12 months. In the further follow-up control intervals were extended up to 1 year in the case of stable anatomical and functional results. RESULTS: All patients showed complete regression of the tumor. The tumor height was reduced from an average of 3.64 mm to undetectable. One patient showed a stable visual acuity, seven patients a significant increase. Central scotometry showed withdrawal of scotomas from the macula. No patient showed any sign of recurrence during the follow-up of up to 60 months. CONCLUSION: The long-term results of patients with active choroidal hemangioma demonstrate that PDT is a most effective and safe treatment option. Complete tumor regression is combined with good functional recovery.
|
Authors | S Michels, R Michels, A Beckendorf, U Schmidt-Erfurth |
Journal | Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
(Ophthalmologe)
Vol. 101
Issue 6
Pg. 569-75
(Jun 2004)
ISSN: 0941-293X [Print] Germany |
Vernacular Title | Photodynamische Therapie bei chorioidalen Hämangiomen. Langzeitergebnisse. |
PMID | 15197573
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Photosensitizing Agents
- Porphyrins
- Verteporfin
|
Topics |
- Adult
- Aged
- Antineoplastic Agents
(administration & dosage)
- Choroid Neoplasms
(diagnosis, drug therapy)
- Female
- Hemangioma
(diagnosis, drug therapy)
- Humans
- Lasers
- Longitudinal Studies
- Male
- Middle Aged
- Neoplasm Recurrence, Local
(diagnosis)
- Photochemotherapy
(methods)
- Photosensitizing Agents
(administration & dosage)
- Porphyrins
(administration & dosage)
- Treatment Outcome
- Verteporfin
|